MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Myriad Genetics Inc

Closed

SectorHealthcare

7.36 1.1

Overview

Share price change

24h

Current

Min

7.2

Max

7.37

Key metrics

By Trading Economics

Income

-20M

-43M

Sales

-2.7M

211M

EPS

0.03

Profit margin

-20.18

Employees

2,700

EBITDA

19M

-2.2M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+102.61% upside

Dividends

By Dow Jones

Next Earnings

6 maj 2025

Market Stats

By TradingEconomics

Market Cap

-435M

704M

Previous open

6.26

Previous close

7.36

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Myriad Genetics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 kwi 2025, 23:54 UTC

Hot Stocks

Stocks to Watch: Alphabet, Intel, AppFolio

24 kwi 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 kwi 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 kwi 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 kwi 2025, 23:37 UTC

Top News

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 kwi 2025, 23:13 UTC

Top News
Earnings

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 kwi 2025, 23:09 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 kwi 2025, 23:02 UTC

Acquisitions, Mergers, Takeovers

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 kwi 2025, 23:02 UTC

Acquisitions, Mergers, Takeovers

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 kwi 2025, 22:51 UTC

Top News
Acquisitions, Mergers, Takeovers

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 kwi 2025, 22:48 UTC

Top News

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 kwi 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 kwi 2025, 22:38 UTC

Market Talk
Earnings

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 kwi 2025, 22:24 UTC

Earnings

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 kwi 2025, 22:24 UTC

Earnings

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 kwi 2025, 22:24 UTC

Market Talk
Earnings

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 kwi 2025, 22:23 UTC

Earnings

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 kwi 2025, 22:11 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

24 kwi 2025, 22:11 UTC

Market Talk
Earnings

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 kwi 2025, 22:09 UTC

Top News
Earnings

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 kwi 2025, 22:00 UTC

Market Talk
Earnings

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 kwi 2025, 21:39 UTC

Top News

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 kwi 2025, 21:24 UTC

Earnings

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 kwi 2025, 21:24 UTC

Top News
Earnings

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 kwi 2025, 21:23 UTC

Top News
Earnings

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 kwi 2025, 21:04 UTC

Earnings

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 kwi 2025, 21:03 UTC

Earnings

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 kwi 2025, 21:03 UTC

Earnings

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 kwi 2025, 21:02 UTC

Earnings

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

24 kwi 2025, 21:02 UTC

Earnings

Agnico-Eagle Mines Positioned to Achieve Its 2025 Total Cash Costs Per Ounce Guidance of $915 to $965 >AEM.T

Peer Comparison

Price change

Myriad Genetics Inc Forecast

Price Target

By TipRanks

102.61% upside

12 Months Forecast

Average 14.77 USD  102.61%

High 22 USD

Low 9 USD

Based on 14 Wall Street analysts offering 12 month price targets forMyriad Genetics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

14 ratings

6

Buy

5

Hold

3

Sell

Technical Score

By Trading Central

7.29 / 7.92Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.